DK3167059T3 - Stabilisering af poly(a)-sekvens, der koder for dna-sekvenser - Google Patents
Stabilisering af poly(a)-sekvens, der koder for dna-sekvenser Download PDFInfo
- Publication number
- DK3167059T3 DK3167059T3 DK15738014.8T DK15738014T DK3167059T3 DK 3167059 T3 DK3167059 T3 DK 3167059T3 DK 15738014 T DK15738014 T DK 15738014T DK 3167059 T3 DK3167059 T3 DK 3167059T3
- Authority
- DK
- Denmark
- Prior art keywords
- stabilization
- poly
- sequence encoding
- dna sequences
- encoding dna
- Prior art date
Links
- 108091028043 Nucleic acid sequence Proteins 0.000 title 1
- 108091034057 RNA (poly(A)) Proteins 0.000 title 1
- 230000006641 stabilisation Effects 0.000 title 1
- 238000011105 stabilization Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
- C12N15/68—Stabilisation of the vector
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2014/064924 WO2016005004A1 (en) | 2014-07-11 | 2014-07-11 | Stabilization of poly(a) sequence encoding dna sequences |
PCT/EP2015/065357 WO2016005324A1 (en) | 2014-07-11 | 2015-07-06 | Stabilization of poly(a) sequence encoding dna sequences |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3167059T3 true DK3167059T3 (da) | 2019-08-05 |
Family
ID=51220548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK15738014.8T DK3167059T3 (da) | 2014-07-11 | 2015-07-06 | Stabilisering af poly(a)-sekvens, der koder for dna-sekvenser |
Country Status (14)
Country | Link |
---|---|
US (2) | US10717982B2 (da) |
EP (2) | EP3167059B1 (da) |
JP (2) | JP6759196B2 (da) |
AU (2) | AU2015286820B2 (da) |
CA (1) | CA2954706C (da) |
DE (2) | DE202015010019U1 (da) |
DK (1) | DK3167059T3 (da) |
ES (1) | ES2735728T3 (da) |
HU (1) | HUE046120T2 (da) |
PL (1) | PL3167059T3 (da) |
PT (1) | PT3167059T (da) |
SI (1) | SI3167059T1 (da) |
TR (1) | TR201910424T4 (da) |
WO (2) | WO2016005004A1 (da) |
Families Citing this family (126)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103906527B (zh) | 2011-06-08 | 2020-07-10 | 川斯勒佰尔公司 | Mrna递送的脂质纳米颗粒组合物和方法 |
ES2670529T3 (es) | 2013-03-15 | 2018-05-30 | Translate Bio, Inc. | Mejora sinergística de la entrega de ácidos nucleicos a través de formulaciones mezcladas |
CA2963840A1 (en) * | 2014-10-09 | 2016-04-14 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Long poly(a) plasmids and methods for introduction of long poly(a) sequences into the plasmid |
WO2016091391A1 (en) | 2014-12-12 | 2016-06-16 | Curevac Ag | Artificial nucleic acid molecules for improved protein expression |
WO2017059902A1 (en) * | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
WO2017162265A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Trans-replicating rna |
WO2017162266A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Rna replicon for versatile and efficient gene expression |
KR102369898B1 (ko) | 2016-04-08 | 2022-03-03 | 트랜슬레이트 바이오 인코포레이티드 | 다량체 코딩 핵산 및 그 용도 |
JP2019522047A (ja) | 2016-06-13 | 2019-08-08 | トランスレイト バイオ, インコーポレイテッド | オルニチントランスカルバミラーゼ欠損症治療のためのメッセンジャーrna療法 |
MA47680A (fr) | 2017-02-28 | 2020-01-08 | Sanofi Sa | Arn thérapeutique |
WO2019036513A1 (en) * | 2017-08-15 | 2019-02-21 | Intellia Therapeutics, Inc. | STABILIZED NUCLEIC ACIDS ENCODING MESSENGER RIBONUCLEIC ACID (MRNA) |
JP7424968B2 (ja) | 2017-09-13 | 2024-01-30 | バイオエヌテック エスエー | 細胞におけるrna発現を増強する方法 |
WO2019053056A1 (en) | 2017-09-13 | 2019-03-21 | Biontech Cell & Gene Therapies Gmbh | RNA REPLICON FOR EXPRESSING A T CELL RECEPTOR OR ARTIFICIAL LYMPHOCYTIC T CELL RECEPTOR |
EP3681993A1 (en) | 2017-09-13 | 2020-07-22 | BioNTech RNA Pharmaceuticals GmbH | Rna replicon for reprogramming somatic cells |
AU2018392716A1 (en) | 2017-12-20 | 2020-06-18 | Translate Bio, Inc. | Improved composition and methods for treatment of ornithine transcarbamylase deficiency |
TW202026423A (zh) | 2018-08-24 | 2020-07-16 | 法商賽諾菲公司 | 用於實體瘤癌症的治療性rna |
JP2022504663A (ja) | 2018-10-11 | 2022-01-13 | エスリス ゲーエムベーハー | セグメント化されたポリ(A)尾部を有するmRNAをコードする配列を含むプラスミド |
WO2020154189A1 (en) | 2019-01-21 | 2020-07-30 | Sanofi | Therapeutic rna and anti-pd1 antibodies for advanced stage solid tumor cancers |
EP3914354A1 (en) | 2019-01-21 | 2021-12-01 | Sanofi | Therapeutic rna for advanced stage solid tumor cancers |
MX2021010862A (es) | 2019-03-12 | 2021-10-22 | BioNTech SE | Arn terapeutico para el cancer de prostata. |
WO2020187848A1 (en) | 2019-03-18 | 2020-09-24 | Biontech Cell & Gene Therapies Gmbh | Lnterleukin-2 receptor (il2r) and interleukin-2 (il2) variants for specific activation of immune effector cells |
WO2020200481A1 (en) | 2019-04-05 | 2020-10-08 | Biontech Rna Pharmaceuticals Gmbh | Treatment involving interleukin-2 (il2) and interferon (ifn) |
BR112021022106A2 (pt) | 2019-05-20 | 2021-12-28 | BioNTech SE | Rna terapêutico para câncer de ovário |
TW202115105A (zh) | 2019-06-24 | 2021-04-16 | 德商拜恩迪克Rna製藥有限公司 | Il2激動劑 |
WO2021008708A1 (en) | 2019-07-18 | 2021-01-21 | Biontech Rna Pharmaceuticals Gmbh | Method for determining at least one parameter of a sample composition comprising nucleic acid, such as rna, and optionally particles |
WO2021058091A1 (en) | 2019-09-24 | 2021-04-01 | Biontech Rna Pharmaceuticals Gmbh | Treatment involving therapeutic antibody and interleukin-2 (il2) |
WO2021129927A1 (en) | 2019-12-23 | 2021-07-01 | Biontech Cell & Gene Therapies Gmbh | Treatment with immune effector cells engineered to express an antigen receptor |
WO2021129945A1 (en) | 2019-12-27 | 2021-07-01 | Biontech Cell & Gene Therapies Gmbh | In vitro and in vivo gene delivery to immune effector cells using nanoparticles functionalized with designed ankyrin repeat proteins (darpins) |
WO2021155916A1 (en) | 2020-02-04 | 2021-08-12 | BioNTech SE | Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137 |
EP4103228A1 (en) | 2020-02-13 | 2022-12-21 | Institut Pasteur | Nucleic acid vaccine against the sars-cov-2 coronavirus |
WO2021175405A1 (en) | 2020-03-02 | 2021-09-10 | Biontech Rna Pharmaceuticals Gmbh | Composite rna particles |
JP2023518935A (ja) | 2020-03-16 | 2023-05-09 | バイオエヌテック セル アンド ジーン セラピーズ ゲーエムベーハー | 抗原特異的t細胞受容体およびt細胞エピトープ |
KR102462990B1 (ko) * | 2020-03-17 | 2022-11-07 | 에이비온 주식회사 | 인비트로 트랜스크립트 mRNA 및 이를 함유하는 약학조성물 |
WO2021198157A1 (en) | 2020-03-30 | 2021-10-07 | BioNTech SE | Rna compositions targeting claudin-18.2 |
WO2021197589A1 (en) | 2020-03-31 | 2021-10-07 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination |
CN111394378A (zh) * | 2020-04-03 | 2020-07-10 | 深圳市新合生物医疗科技有限公司 | 一种体外表达mRNA的质粒载体及其构建方法和应用 |
KR20230015351A (ko) | 2020-04-22 | 2023-01-31 | 화이자 인코포레이티드 | 코로나바이러스 백신 |
MX2022013254A (es) | 2020-04-22 | 2023-01-24 | BioNTech SE | Vacuna contra el coronavirus. |
AU2021286169A1 (en) | 2020-06-04 | 2023-01-19 | BioNTech SE | RNA replicon for versatile and efficient gene expression |
JP2023532768A (ja) | 2020-07-07 | 2023-07-31 | バイオエヌテック エスエー | Hpv陽性癌の治療用rna |
AU2021322046A1 (en) | 2020-08-06 | 2023-02-02 | BioNTech SE | Binding agents for coronavirus S protein |
TW202227478A (zh) | 2020-09-15 | 2022-07-16 | 德商拜恩迪克公司 | 對細胞靶向遞送的藥劑及方法 |
US20230399403A1 (en) | 2020-11-11 | 2023-12-14 | BioNTech SE | Monoclonal antibodies directed against programmed death-1 protein and their use in medicine |
US20240041785A1 (en) | 2020-11-16 | 2024-02-08 | BioNTech SE | Compositions and methods for stabilization of lipid nanoparticle mrna vaccines |
TW202237148A (zh) | 2020-11-16 | 2022-10-01 | 德商拜恩迪克公司 | 包含rna之lnp組合物以及製備、儲存及使用彼之方法 |
WO2022218503A1 (en) | 2021-04-12 | 2022-10-20 | BioNTech SE | Lnp compositions comprising rna and methods for preparing, storing and using the same |
US20240033344A1 (en) | 2020-11-16 | 2024-02-01 | BioNTech SE | Pharmaceutical compositions comprising particles and mrna and methods for preparing and storing the same |
CA3201552A1 (en) | 2020-12-09 | 2022-06-16 | Thomas ZIEGENHALS | Rna manufacturing |
WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性rna |
WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
CA3215103A1 (en) | 2021-04-12 | 2022-10-20 | Steffen Panzner | Rna compositions comprising a buffer substance and methods for preparing, storing and using the same |
CN117750974A (zh) | 2021-04-20 | 2024-03-22 | 生物技术欧洲股份公司 | 病毒疫苗 |
KR20240006575A (ko) | 2021-04-26 | 2024-01-15 | 앵스띠뛰 파스퇴르 | SARS-CoV-2에 대한 사람 중화 모노클로날 항체 및 이의 용도 |
AU2022270658A1 (en) | 2021-05-04 | 2023-11-16 | BioNTech SE | Technologies for early detection of variants of interest |
CN117715655A (zh) | 2021-06-08 | 2024-03-15 | 生物技术细胞和基因治疗公司 | 用于活化和靶向免疫效应细胞的物质和方法 |
CA3226700A1 (en) | 2021-07-15 | 2023-01-19 | BioNTech SE | Agents encoding cldn6 and cds binding elements for treating cldn6-positive cancers |
CA3223943A1 (en) | 2021-07-29 | 2023-02-02 | Ugur Sahin | Compositions and methods for treatment of melanoma |
KR20230026965A (ko) * | 2021-08-17 | 2023-02-27 | 에스케이바이오사이언스(주) | 폴리 a 테일을 안정적으로 유지하는 방법 |
WO2023025404A1 (en) | 2021-08-24 | 2023-03-02 | BioNTech SE | In vitro transcription technologies |
WO2023030635A1 (en) | 2021-09-02 | 2023-03-09 | BioNTech SE | Potency assay for therapeutic potential of coding nucleic acid |
WO2023036960A1 (en) | 2021-09-10 | 2023-03-16 | BioNTech SE | Lipid-based rna formulations suitable for therapy |
WO2023051926A1 (en) | 2021-09-30 | 2023-04-06 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists |
TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
TW202333803A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(一) |
WO2023061550A1 (en) | 2021-10-11 | 2023-04-20 | BioNTech SE | Therapeutic rna for lung cancer |
TW202327646A (zh) | 2021-10-15 | 2023-07-16 | 美商輝瑞大藥廠 | Rna分子 |
WO2023064612A2 (en) | 2021-10-15 | 2023-04-20 | BioNTech SE | Pharmaceutical compositions for delivery of viral antigens and related methods |
AU2022372325A1 (en) | 2021-10-18 | 2024-05-02 | BioNTech SE | Methods for determining mutations for increasing modified replicable rna function and related compositions and their use |
AU2022369342A1 (en) | 2021-10-18 | 2024-03-14 | BioNTech SE | Modified replicable rna and related compositions and their use |
AU2021470029A1 (en) | 2021-10-21 | 2024-05-02 | BioNTech SE | Coronavirus vaccine |
EP4285933A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharide complexes and uses |
EP4286394A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharide compounds and complexes |
EP4286004A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Disulfide oligosaccharide compounds and complexes |
WO2023067125A1 (en) | 2021-10-22 | 2023-04-27 | BioNTech SE | Oligosaccharide complexes and uses |
EP4286003A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharide compounds and complexes |
EP4169579A1 (en) | 2021-10-22 | 2023-04-26 | BioNTech SE | Disulfide oligosaccharide compounds and complexes |
EP4169580A1 (en) | 2021-10-22 | 2023-04-26 | BioNTech SE | Oligosaccharide compounds and complexes |
WO2023067126A1 (en) | 2021-10-22 | 2023-04-27 | BioNTech SE | Oligosaccharide compounds and complexes |
WO2023067121A1 (en) | 2021-10-22 | 2023-04-27 | BioNTech SE | Oligosaccharide compounds and complexes |
WO2023067124A1 (en) | 2021-10-22 | 2023-04-27 | BioNTech SE | Disulfide oligosaccharide compounds and complexes |
EP4186528A1 (en) | 2021-11-30 | 2023-05-31 | BioNTech SE | Oligosaccharide complexes and uses |
EP4285932A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharide complexes and uses |
AU2022374004A1 (en) | 2021-10-22 | 2024-05-02 | BioNTech SE | Compositions for administration of different doses of rna |
EP4169578A1 (en) | 2021-10-22 | 2023-04-26 | BioNTech SE | Oligosaccharide compounds and complexes |
EP4169534A1 (en) | 2021-10-22 | 2023-04-26 | BioNTech SE | Oligosaccharide complexes and uses |
WO2023067123A1 (en) | 2021-10-22 | 2023-04-27 | BioNTech SE | Oligosaccharide complexes and uses |
WO2023073190A1 (en) | 2021-10-28 | 2023-05-04 | BioNTech SE | Rna constructs and uses thereof |
WO2023083434A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Rna encoding peptidoglycan hydrolase and use thereof for treating bacterial infection |
GB2615177A (en) | 2021-11-29 | 2023-08-02 | BioNTech SE | Coronavirus vaccine |
WO2023105005A1 (en) | 2021-12-09 | 2023-06-15 | BioNTech SE | Chimeric antigen receptor-modified cells for the treatment of cldn6 expressing cancer |
WO2024046572A1 (en) | 2022-09-01 | 2024-03-07 | BioNTech SE | Chimeric antigen receptor-modified cells for the treatment of cldn6 expressing cancer |
WO2023126053A1 (en) | 2021-12-28 | 2023-07-06 | BioNTech SE | Lipid-based formulations for administration of rna |
WO2023147090A1 (en) | 2022-01-27 | 2023-08-03 | BioNTech SE | Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods |
WO2023147092A2 (en) | 2022-01-28 | 2023-08-03 | BioNTech SE | Coronavirus vaccine |
WO2023148277A1 (en) | 2022-02-02 | 2023-08-10 | BioNTech SE | Agents and methods for targeted delivery of nucleic acids to cells |
WO2023148276A1 (en) | 2022-02-02 | 2023-08-10 | BioNTech SE | Agents and methods for targeted delivery to cells |
WO2023165681A1 (en) | 2022-03-01 | 2023-09-07 | BioNTech SE | Rna lipid nanoparticles (lnps) comprising a polyoxazoline and/or polyoxazine polymer |
WO2023174521A1 (en) | 2022-03-15 | 2023-09-21 | Genmab A/S | Binding agents binding to epcam and cd137 |
WO2023193892A1 (en) | 2022-04-05 | 2023-10-12 | BioNTech SE | Nucleic acid compositions comprising an inorganic polyphosphate and methods for preparing, storing and using the same |
WO2023213378A1 (en) | 2022-05-02 | 2023-11-09 | BioNTech SE | Replicon compositions and methods of using same for the treatment of diseases |
WO2023217987A1 (en) | 2022-05-12 | 2023-11-16 | BioNTech SE | Monoclonal antibodies directed against programmed death-1 protein and their use in medicine |
WO2023218431A1 (en) | 2022-05-13 | 2023-11-16 | BioNTech SE | Rna compositions targeting hiv |
WO2023230295A1 (en) | 2022-05-25 | 2023-11-30 | BioNTech SE | Rna compositions for delivery of monkeypox antigens and related methods |
WO2023232747A1 (en) | 2022-05-30 | 2023-12-07 | BioNTech SE | Complexes for delivery of nucleic acids |
WO2023234661A1 (ko) * | 2022-05-31 | 2023-12-07 | 경상국립대학교산학협력단 | 신규한 변형 폴리아데닌 서열 및 이의 용도 |
US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
WO2024017479A1 (en) | 2022-07-21 | 2024-01-25 | BioNTech SE | Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production |
WO2024028325A1 (en) | 2022-08-01 | 2024-02-08 | BioNTech SE | Nucleic acid compositions comprising amphiphilic oligo ethylene glycol (oeg)-conjugated compounds and methods of using such compounds and compositions |
WO2024028445A1 (en) | 2022-08-03 | 2024-02-08 | BioNTech SE | Rna for preventing or treating tuberculosis |
WO2024027910A1 (en) | 2022-08-03 | 2024-02-08 | BioNTech SE | Rna for preventing or treating tuberculosis |
CN117701602A (zh) * | 2022-08-26 | 2024-03-15 | 深圳瑞吉生物科技有限公司 | 在宿主细胞中稳定存在的多段化PolyA多核苷酸及其应用 |
WO2024056856A1 (en) | 2022-09-15 | 2024-03-21 | BioNTech SE | Systems and compositions comprising trans-amplifying rna vectors with mirna |
WO2024064931A1 (en) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of liver stage antigens and related methods |
WO2024063788A1 (en) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of malaria antigens and related methods |
WO2024063789A1 (en) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of malaria antigens and related methods |
WO2024064934A1 (en) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of plasmodium csp antigens and related methods |
WO2024068674A1 (en) | 2022-09-26 | 2024-04-04 | BioNTech SE | Nucleic acid complexes and uses thereof |
WO2024075022A2 (en) | 2022-10-04 | 2024-04-11 | BioNTech SE | Rna constructs and uses thereof |
WO2024074634A1 (en) | 2022-10-06 | 2024-04-11 | BioNTech SE | Rna compositions targeting claudin-18.2 |
WO2024074211A1 (en) | 2022-10-06 | 2024-04-11 | BioNTech SE | Rna compositions targeting claudin-18.2 |
WO2024086575A1 (en) | 2022-10-17 | 2024-04-25 | BioNTech SE | Combination vaccines against coronavirus infection, influenza infection, and/or rsv infection |
WO2024083345A1 (en) | 2022-10-21 | 2024-04-25 | BioNTech SE | Methods and uses associated with liquid compositions |
WO2024084462A1 (en) | 2022-10-21 | 2024-04-25 | BioNTech SE | Nucleic acid complexes and uses thereof |
WO2024089634A1 (en) | 2022-10-27 | 2024-05-02 | Pfizer Inc. | Immunogenic compositions against influenza and rsv |
WO2024089633A1 (en) | 2022-10-27 | 2024-05-02 | Pfizer Inc. | Rna molecules encoding rsv-f and vaccines containing them |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5866422A (en) * | 1997-10-29 | 1999-02-02 | New England Biolabs, Inc. | Method for cloning and producing the Tsp45I restriction endonuclease in E. coli |
WO2001064749A2 (en) * | 2000-02-28 | 2001-09-07 | Idec Pharmaceuticals Corporation | Method for preparing anti-mif antibodies |
DE102005046490A1 (de) * | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
AU2011253592B2 (en) * | 2005-09-28 | 2013-11-14 | Biontech Ag | Modification of RNA, producing an increased transcript stability and translation efficiency |
US9249425B2 (en) * | 2011-05-16 | 2016-02-02 | The Trustees Of The University Of Pennslyvania | Proviral plasmids and production of recombinant adeno-associated virus |
-
2014
- 2014-07-11 WO PCT/EP2014/064924 patent/WO2016005004A1/en active Application Filing
-
2015
- 2015-07-06 DE DE202015010019.8U patent/DE202015010019U1/de active Active
- 2015-07-06 CA CA2954706A patent/CA2954706C/en active Active
- 2015-07-06 PL PL15738014T patent/PL3167059T3/pl unknown
- 2015-07-06 TR TR2019/10424T patent/TR201910424T4/tr unknown
- 2015-07-06 EP EP15738014.8A patent/EP3167059B1/en active Active
- 2015-07-06 AU AU2015286820A patent/AU2015286820B2/en active Active
- 2015-07-06 DE DE202015010020.1U patent/DE202015010020U1/de active Active
- 2015-07-06 ES ES15738014T patent/ES2735728T3/es active Active
- 2015-07-06 US US15/325,280 patent/US10717982B2/en active Active
- 2015-07-06 SI SI201530850T patent/SI3167059T1/sl unknown
- 2015-07-06 DK DK15738014.8T patent/DK3167059T3/da active
- 2015-07-06 EP EP19180818.7A patent/EP3594337A1/en active Pending
- 2015-07-06 HU HUE15738014A patent/HUE046120T2/hu unknown
- 2015-07-06 PT PT15738014T patent/PT3167059T/pt unknown
- 2015-07-06 WO PCT/EP2015/065357 patent/WO2016005324A1/en active Application Filing
- 2015-07-06 JP JP2017521299A patent/JP6759196B2/ja active Active
-
2020
- 2020-05-13 JP JP2020084559A patent/JP7144481B2/ja active Active
- 2020-06-10 US US16/898,176 patent/US20200392518A1/en active Pending
-
2021
- 2021-12-06 AU AU2021277776A patent/AU2021277776A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US10717982B2 (en) | 2020-07-21 |
PT3167059T (pt) | 2019-07-29 |
US20170166905A1 (en) | 2017-06-15 |
JP2020188758A (ja) | 2020-11-26 |
DE202015010019U1 (de) | 2023-06-02 |
CA2954706C (en) | 2023-01-24 |
DE202015010020U1 (de) | 2023-06-05 |
US20200392518A1 (en) | 2020-12-17 |
AU2015286820B2 (en) | 2021-09-09 |
ES2735728T3 (es) | 2019-12-20 |
JP2017522050A (ja) | 2017-08-10 |
JP7144481B2 (ja) | 2022-09-29 |
EP3167059A1 (en) | 2017-05-17 |
WO2016005324A1 (en) | 2016-01-14 |
SI3167059T1 (sl) | 2019-10-30 |
AU2021277776A1 (en) | 2021-12-23 |
PL3167059T3 (pl) | 2019-12-31 |
JP6759196B2 (ja) | 2020-09-23 |
EP3167059B1 (en) | 2019-06-26 |
EP3594337A1 (en) | 2020-01-15 |
AU2015286820A1 (en) | 2017-02-23 |
AU2015286820A8 (en) | 2017-03-30 |
WO2016005004A1 (en) | 2016-01-14 |
HUE046120T2 (hu) | 2020-02-28 |
TR201910424T4 (tr) | 2019-08-21 |
CA2954706A1 (en) | 2016-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3167059T3 (da) | Stabilisering af poly(a)-sekvens, der koder for dna-sekvenser | |
DK3337902T3 (da) | 3'-utr-sekvenser til stabilisering af rna | |
DK3256853T3 (da) | Forudsigelse af t-celleepitoper, der er egnede til vaccination | |
DK3461821T3 (da) | Indolcarboxamidforbindelser, der er brugbar som kinasehæmmere | |
DK3165507T3 (da) | Fremgangsmåde til fremstilling af porøs grafen | |
DK3186376T3 (da) | Fremgangsmåder til forbedring af cas9-medieret manipulationseffektivitet | |
DK3286311T3 (da) | Fremgangsmåde til behandling af maligniteter | |
DK3294700T3 (da) | Fremgangsmåde til fremstilling af limonen-4-ol | |
DK3230410T3 (da) | Katalysator til hydrogenering af aromatiske forbindelser, dens fremstilling og anvendelse deraf | |
DK3344805T3 (da) | Fremgangsmåde til udvælgelse af aptamerer til ubundne mål | |
DK3303618T3 (da) | Fremgangsmåder til prognose af prostatacancer | |
DK3721997T3 (da) | Fremgangsmåde til fremstilling af en katalysator | |
DK3177670T3 (da) | Hyperforgrenet poly(beta-aminoester) til genterapi | |
DK3464306T3 (da) | Fremgangsmåder til fremstilling af phosphorodiamidat-morpholino-oligomerer | |
DK3235819T3 (da) | Pyrrolopyrimidinforbindelser, der er anvendelige som JAK-inhibitorer | |
DK3141454T3 (da) | Vogn til bæring af varer | |
DK3436589T3 (da) | Ny minimale utr-sekvenser | |
DK3170734T3 (da) | Fremgangsmåde til drift af en motor for et fartøj | |
DK3310369T3 (da) | Selvbegrænsende virale vektorer, der koder for nukleaser | |
DK3237362T3 (da) | Fremgangsmåder til fremstilling af oligomerer af en olefin | |
DK3370804T3 (da) | Patronbæreranordning | |
DK3347360T3 (da) | Forbindelser, som er anvendelige til inhibering af ror-gamma-t | |
DK3274143T3 (da) | Fremgangsmåde til fremstilling af lignocellulosematerialer | |
DK3237363T3 (da) | Fremgangsmåder til at fremstille oligomerer af en olefin | |
DK3175593T3 (da) | Signalering af modulationskonfiguration |